Proteros biostructures GmbH

Proteros biostructures and Orion Pharma agree on long-term multi-target collaboration including assembly of a joint novel and unique HTS small-molecule library with full chemistry support of Enamine

Proteros receives minority investment from private equity firm Inflexion

Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

Proteros, co-founder of Rodin Therapeutics, announces Rodin’s acquisition by Alkermes

Proteros biostructures GmbH names Dave Lemus as new executive board member

Proteros enters into new research collaboration with Johnson & Johnson Innovation on sub-class of epigenetic targets

Proteros biostructures GmbH: 23rd Conference on Protein Structure Determination in Industry (PSDI) discussing important impact of structural biology for drug discovery

Proteros signs new oncology collaboration with Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA on epigenetic target

Proteros Appoints Dr. Torsten Hoffmann as Chief Scientific Officer

Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration

Proteros geht Kooperation mit Bayer zur Entwicklung neuer kardiovaskulärer Wirkstoffe für integrales Membranprotein ein

Update of release from 29.05.2014, 13:29 CET: Proteros announces a USD 12.9 million Series A Financing of Rodin Therapeutics

Proteros announces a USD 12 million Series A Financing of Rodin Therapeutics, a Company founded by Atlas Venture and Proteros, Focussing on Novel Treatments for CNS Disorders

Proteros biostructures GmbH: Proteros Announces Changes in Management Team

Proteros biostructures GmbH Announces Election of Prof. Eric-Paul Pâques, CEO of Grünenthal, as New Supervisory Board Member